Literature DB >> 2138903

Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance in vivo.

E Jähde1, K H Glüsenkamp, M F Rajewsky.   

Abstract

In malignant tumors the distribution of pH values is shifted to lower values (range, pH 5.8-7.4) as compared to normal tissues (range, pH 6.9-7.4) or peripheral blood (pH 7.35-7.45). We have investigated whether the cytotoxic effect of the anthracenedione anti-cancer drug mitoxantrone (MX) on malignant cells in culture is dependent on changes of extracellular pH. The clonogenic fraction of M1R rat mammary carcinoma cells was measured after exposure to MX at an extracellular pH (pHe) of 6.5-7.4. At pHe 6.8 (approximately the average pH measured in a number of malignant tumors in vivo) the clonogenic fraction of M1R cells exposed to MX (0.1 microgram/ml) only decreased to 1 X 10(-1) as compared to 2.5 X 10(-4) at pHe 7.4, corresponding to a 400-fold inhibition of MX cytotoxicity at reduced environmental pH. The H+ ion-mediated resistance of M1R cells to MX could be partially reversed by verapamil, suggesting that a reduced microenvironmental pH possibly interferes with intracellular MX accumulation. Therefore, drugs like MX may not be effective in the elimination of cells in acidic tumor areas. Moreover, investigations on anti-cancer drug activity in vitro at what is frequently referred to as 'physiological pH' may be irrelevant in terms of the cytotoxic effects of the respective agents at the pH values prevailing in malignant tissues in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138903     DOI: 10.1016/0277-5379(90)90290-a

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Acid-mediated tumor proteolysis: contribution of cysteine cathepsins.

Authors:  Jennifer M Rothberg; Kate M Bailey; Jonathan W Wojtkowiak; Yael Ben-Nun; Matthew Bogyo; Ekkehard Weber; Kamiar Moin; Galia Blum; Raymond R Mattingly; Robert J Gillies; Bonnie F Sloane
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 2.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

Authors:  Jonathan W Wojtkowiak; Daniel Verduzco; Karla J Schramm; Robert J Gillies
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

3.  Mechanisms of buffer therapy resistance.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Heather H Cornnell; Maria C Ribeiro; Yoganand Balagurunathan; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

4.  Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.

Authors:  C van Bree; E M Schopman; P J Bakker; J B Kipp; G W Barendsen
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

6.  Monitoring extracellular ion and metabolite dynamics with recombinant nanobody-fused biosensors.

Authors:  Sandra Burgstaller; Teresa R Wagner; Helmut Bischof; Sarah Bueckle; Aman Padamsey; Desiree Frecot; Philipp D Kaiser; David Skrabak; Roland Malli; Robert Lukowski; Ulrich Rothbauer
Journal:  iScience       Date:  2022-08-10

7.  Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.

Authors:  V Vukovic; I F Tannock
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells.

Authors:  O K Schlappack; A Zimmermann; R P Hill
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

9.  Cytotoxicity of weak electrolytes after the adaptation of cells to low pH: role of the transmembrane pH gradient.

Authors:  S V Kozin; L E Gerweck
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.